MedPath

Cytarabine

Cytarabine Injection(For Intravenous or Subcutaneous Use)

Approved
Approval ID

1be2668b-d76f-4c65-aea9-86c5c40889a2

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 6, 2022

Manufacturers
FDA

Meitheal Pharmaceuticals Inc.

DUNS: 080548348

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cytarabine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71288-168
Application NumberANDA206190
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cytarabine
Product Specifications
Route of AdministrationINTRAVENOUS, SUBCUTANEOUS
Effective DateJanuary 11, 2022
FDA Product Classification

INGREDIENTS (5)

hydrochloric acidInactive
Code: QTT17582CB
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT
sodium chlorideInactive
Code: 451W47IQ8X
Classification: IACT
cytarabineActive
Quantity: 20 mg in 1 mL
Code: 04079A1RDZ
Classification: ACTIB
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cytarabine - FDA Drug Approval Details